Begoña Navarro-Almenzar

Dr. Begoña Navarro-Almenzar

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
FCFerran Celma
Ferran Celma
GVGonzalo Hernandez Viedma
Gonzalo Hernandez Viedma
XFXènia Ferrer-Cortès
Xènia Ferrer-Cortès
IHInes Hernandez-Rodriguez
Ines Hernandez-Rodriguez
BNBegoña Navarro-Almenzar
Begoña Navarro-Almenzar
MSMayka Sanchez
Mayka Sanchez
Hereditary hyperferritinemia-cataract syndrome (HHCS) is a rare disease characterized by high serum ferritin levels, congenital bilateral cataracts, and the absence of tissue iron overload. This disorder is produced by mutations in the iron responsive element (IRE) located in the 5′ untranslated regions (UTR) of the light ferritin (FTL) gene. A canonical IRE is a mRNA structure that interacts with the iron regulatory proteins (IRP1 and IRP2) to post-transcriptionally regulate the expression of proteins related to iron metabolism. Ferritin L and H are the proteins responsible for iron storage and intracellular distribution. Mutations in the FTL IRE abrogate the interaction of FTL mRNA with the IRPs, and de-repress the expression of FTL protein. Subsequently, there is an overproduction of ferritin that accumulates in serum (hyperferritinemia) and excess ferritin precipitates in the lens, producing cataracts. To illustrate this disease, we report two new families affected with hereditary hyperferritinemia-cataract syndrome with previous known mutations. In the diagnosis of congenital bilateral cataracts, HHCS should be taken into consideration and, therefore, it is important to test serum ferritin levels in patients with cataracts.

11 September 2019 in Current Medical Research and Opinion
Verified
Journal Article
Closed access
BNBegoña Navarro-Almenzar
Begoña Navarro-Almenzar
JCJuan José Cerezo-Manchado
Juan José Cerezo-Manchado
CCCésar Caro-Martinez
César Caro-Martinez
FGFaustino García-Candel
Faustino García-Candel
PBPedro José Flores Blanco
Pedro José Flores Blanco
SMSergio Manzano-Fernández
Sergio Manzano-Fernández
Aim: To analyse the effectiveness and safety of DOAC (direct oral anticoagulants) in nonvalvular atrial fibrillation (NVAF) patients attending clinical practice. Methods: Retrospective study of AF patients who started treatment with DOAC from January 1, 2013 to December 31, 2016 in three Spanish hospitals. Mean follow up was 1.6 years. The primary outcomes were rates of all-cause death, ischemic stroke and bleeding. We also studied these outcomes depending on correct dosage adjustment and standard/adjusted dose. Results: The study included 2494 patients (age 76.0 ± 9.5 years, CHA2DS2-VASc =4.0 ± 1.6). The most prescribed DOAC was rivaroxaban (41.1%). Patients taking dabigatran were the youngest (mean age 73.1 ± 10.3 years), with better kidney function (mean CrCl 80.6 ± 35.8 ml/min) and lower CHA2DS2-VASc (3.7 ± 1.4) and HAS-BLED (2.1 ± 0.9) scores. Patients taking apixaban were the oldest, and had the highest CHA2DS2-VASc and HAS-BLED scores (4.3 ± 1.6 and 2.6 ± 0.9 respectively). Rates of stroke/major bleeding/intracranial bleeding were 1.8/3.0/0.3 events per 100 patient-years, respectively, with no differences among DOAC. Based on dose adjustment according to technical data, we observed that 517 patients (23.5%) received DOAC doses inconsistent with labelling (p < 0.001) and, within this group, underdosed patients had a higher death rate although it did not reach a significant result after multivariate adjustment. Conclusion: Our results of safety and efficacy are very similar to those of other previously published national registries. There were no differences among the different types of DOAC regarding outcomes. However, it was found that people taking the adjusted dose of the drug seemed to have a higher risk of death. A non-negligible proportion of patients received DOAC doses inconsistent with labelling (mostly underdose).

11 November 2021 in IJC Heart & Vasculature
Verified
Journal Article
Open access
BNBegoña Navarro-Almenzar
Begoña Navarro-Almenzar
JCJuan José Cerezo-Manchado
Juan José Cerezo-Manchado
FGFaustino García-Candel
Faustino García-Candel
Atrial fibrillation (AF) is the most prevalent arrhythmia worldwide and the main cause of anticoagulation, being direct oral anticoagulants (DOAC) increasingly used in this context. On the other hand, obesity is a known risk thromboembolic factor. In the clinical trials that led to the approval of DOAC for ischemic stroke prevention, patients with morbid obesity were underrepresented. The International Society of Thrombosis and Haemostasis suggests not using these drugs in morbid obese patients. Thus, the primary objectives of this study were to analyse the rates of mortality, thrombotic and haemorrhagic events in patients with morbid obesity. As secondary objectives, factors statistically associated with these events were analysed. Methods: multicentre retrospective study that included patients diagnosed with AF on treatment with DOAC from January 2013 to December 2016. The subgroup of patients with morbid obesity (BMI > 40 and / or weight > 120 kg) was analysed. Mean follow-up was 1.7 years. Results: Amongst 2,492 patients included in the study, 135 patients had morbid obesity (mean age was 71 ± 11 years). The mean scores of the CHA2DS2-VASc and HAS-BLED risk scales were 3.7 ± 1.6 and 2.2 ± 0.9, respectively. Neither differences were found regarding mortality (5.2 vs 6/100 patient-years, p = 0.662), ischemic stroke (0.8 vs 1.9/100 patient-years, p = 0.261) and major bleeding rates (3 vs 3.1/100 patient-years, p = 0.983) between morbidly obese population and general population. Nor was there an association found between the degree of obesity and any of the events studied. Conclusion: DOAC are safe and effective in morbidly obese patients.

1 June 2020 in Medicina Clinica
Verified
Journal Article
Closed access
BNBegoña Navarro-Almenzar
Begoña Navarro-Almenzar
VPValentín Cabañas Perianes
Valentín Cabañas Perianes

1 August 2020 in Enfermedades Infecciosas y Microbiología Clínica
Verified
Journal Article
Closed access
BNBegoña Navarro-Almenzar
Begoña Navarro-Almenzar
FCFrancisco López Castaño
Francisco López Castaño
BOBeatriz Hurtado Oliver
Beatriz Hurtado Oliver